HCPCS Code J2353: Octreotide depot billing guide

Key Takeaways

HCPCS Code J2353 describes injection, octreotide, depot form, 1 mg (Sandostatin LAR Depot) billed at 1 unit per mg administered.

Medicare Part B reimburses J2353 at ASP + 6% under the buy-and-bill model; prior authorization requirements vary by MAC and commercial payer.

Covered diagnoses include acromegaly (E22.0), carcinoid syndrome (E34.00, E34.01, or E34.09), and VIPoma; claims without a valid paired ICD-10 code are a leading cause of denials.

Pabau’s claims management software supports injectable drug billing workflows, tracking prior authorization status and pairing diagnosis codes before claim submission.

HCPCS Code J2353 is the billing code for injection, octreotide, depot form, 1 mg (Sandostatin LAR Depot). This guide covers Medicare coverage rules, covered ICD-10 diagnoses, prior authorization requirements, documentation standards, fee schedule data, and how J2353 differs from J2354.

HCPCS Code J2353: definition and clinical description

HCPCS Code J2353 is the Level II HCPCS code for injection, octreotide, depot form, 1 mg. According to the Centers for Medicare and Medicaid Services (CMS), J2353 applies exclusively to the long-acting release (LAR) depot formulation of octreotide, sold under the brand name Sandostatin LAR Depot by Novartis. It does not apply to immediate-release octreotide (see J2354 below).

One billing unit equals 1 mg of octreotide depot. Typical doses run 10 mg, 20 mg, or 30 mg per injection, administered intramuscularly once every four weeks, so most claims will report 10, 20, or 30 units depending on the prescribed dose. Billing the wrong unit count is among the most common J2353 errors.

The same unit-per-mg logic applies to other injectable J-codes, including J7326, so it pays to double-check the billed quantity against the administered dose every time.

Code details at a glance

The table below consolidates the key administrative data for J2353 from CMS and AAPC sources. Use this as a quick reference before building a claim.

For a broader lookup of HCPCS Level II injectable codes, the AAPC Codify HCPCS database provides code descriptions, effective dates, and related code cross-references. Also see this procedure code reference for how injectable drug codes are structured across different billing systems.

Medicare coverage and reimbursement for J2353

HCPCS Code J2353 is covered under Medicare Part B as a physician-administered drug. Coverage is governed by CMS Billing and Coding Article 56531, which defines the covered indications, documentation requirements, and billing rules.

Reimbursement follows the standard Part B drug formula: Average Sales Price (ASP) + 6%. CMS updates ASP-based allowable amounts quarterly. Because ASP figures change each quarter, always verify the current rate against the CMS quarterly ASP Drug Pricing Files before submitting claims.

The buy-and-bill model applies. Under this pathway, the physician or practice purchases the drug, administers it in-office, and bills Medicare directly using J2353 paired with an administration code.

Use the CMS Physician Fee Schedule search tool to look up the administration code payment; for the drug-specific rate, check the CMS quarterly ASP Drug Pricing File or the Part B Drug Payment Limit File instead.

Part B vs. Part D: which covers J2353?

When octreotide depot is administered by a physician in a clinical setting, Part B covers the drug and the administration. When a patient self-administers at home, Part D may apply instead. Billing under the wrong benefit part is a common source of claim rejections.

Covered indications: ICD-10 codes for J2353

Every J2353 claim requires a valid paired ICD-10-CM diagnosis code that matches a CMS-covered indication. Per CMS Article A56531, the primary covered diagnoses are acromegaly, carcinoid syndrome, and VIPoma. ICD-10-CM codes map to billing claims differently across specialties, including endocrinology practices running metabolic health EMR software.

ICD-10 code coverage for J2353 is governed by Local Coverage Determinations (LCDs) issued by individual Medicare Administrative Contractors (MACs). The table above reflects common covered codes per CMS Article A56531, but always verify the complete, current ICD-10 list against your MAC’s active LCD before submitting a claim. Coverage lists can expand or contract with annual LCD updates.

Prior authorization requirements for J2353

Prior authorization (PA) requirements for HCPCS Code J2353 vary by MAC and commercial payer. CMS does not impose a universal PA requirement under Medicare, but individual MACs may require it under their LCD policies.

• Medicare (Part B): PA requirements depend on the MAC jurisdiction. Check your MAC’s LCD and any associated Billing and Coding Articles before the first administration.
• Commercial payers: Most major commercial plans require PA for Sandostatin LAR Depot due to its high cost, a pattern also common among practices running HRT clinic software for other high-cost hormone injectables. Submit clinical documentation including diagnosis, previous treatment history, and the prescribing physician’s assessment.
• Medicaid: State-specific PA rules apply. Requirements and covered diagnoses vary significantly across state programs.
• What to submit for PA: Diagnosis with supporting ICD-10 code, relevant lab values (IGF-1 levels for acromegaly, 5-HIAA for carcinoid), prior treatment history, and the treating physician’s clinical notes.

Submitting a claim without an approved PA when one is required is one of the most common denial causes for J2353. Tracking PA status before each administration cycle reduces this risk. Pabau’s claims management software flags codes that require PA before claim submission, helping billing teams catch missing authorizations before they become denials.

J2353 billing guidelines and units

Billing J2353 correctly means getting the unit count right, pairing the correct administration code, and applying the right place of service. Each of these is a distinct failure point.

Unit calculation

One unit of J2353 equals 1 mg. Bill exactly the number of milligrams dispensed and administered. For a 20 mg injection, report 20 units. For a 30 mg injection, report 30 units. Never round to a standard dose without confirming what was actually administered.

Administration codes to pair with J2353

Octreotide depot is administered by intramuscular (IM) injection by a qualified healthcare professional. For Medicare Part B claims, pair J2353 with the appropriate administration CPT code.

The most common pairing is CPT 96372 (therapeutic, prophylactic, or diagnostic injection, subcutaneous or intramuscular). Place of service should reflect where the injection occurred: office (11), hospital outpatient (22), or off-campus outpatient hospital (19) as applicable.

Billing frequency

Sandostatin LAR Depot is typically administered once every four weeks. Most payers’ medical policies reflect this dosing interval. Billing more frequently than once per 28 days may trigger a medical review or automatic denial without supporting clinical documentation justifying the deviation.

Other injectable codes carry the same interaction risk between dosing and documentation. J2997 follows a comparable ASP-based reimbursement structure for infused therapies, which is why matching the administered dose to the billed units matters across the board.

Simplify injectable drug billing

Pabau helps endocrinology and oncology practices manage J-code billing workflows, track prior authorization status, and link clinical documentation to claims before submission.

Book a demo

Documentation requirements for J2353 claims

Insufficient documentation is the second leading cause of J2353 claim denials after missing PA. Per CMS Article A56531, the medical record must support medical necessity for each administration. Refer to this overview of clinical recordkeeping for broader context on documentation best practices across specialties.

• Diagnosis documentation: The record must include the confirmed diagnosis with relevant clinical findings (e.g., elevated IGF-1 levels for acromegaly).
• Prescription and order: A physician order for the specific dose administered, signed and dated.
• Administration record: Date of administration, dose in mg, route (IM), site, lot number, and expiration date of the vial.
• Prior authorization approval: If PA was required, include the authorization number in the claim and retain a copy of the approval in the patient record.
• Medical necessity narrative: For high-cost drugs, some MACs require a brief narrative explaining why the therapy is medically necessary for this specific patient, particularly for initial claims or dose changes.

Maintaining HIPAA-compliant recordkeeping for all documentation tied to J2353 claims is also a legal requirement. Records must be retained per your state’s medical records retention laws, which typically range from 5 to 10 years.

Pabau links clinical documentation to billing codes, enabling billing teams to verify that required documentation is in place before a claim leaves the practice. This is especially useful for J-codes like J2353, where missing a single document often means a denial rather than just a delay.

J2353 fee schedule and ASP pricing

Medicare reimburses J2353 based on the drug’s Average Sales Price (ASP) plus 6%. Because ASP is recalculated each calendar quarter from manufacturer-reported sales data, the allowable amount changes four times per year. There is no fixed annual fee schedule amount for J2353 the way there is for office visit E/M codes.

To find the current quarter’s allowable amount, use the CMS Physician Fee Schedule lookup tool or download the quarterly ASP Drug Pricing File from the CMS website. The table below illustrates how the billing math works, using a hypothetical ASP for reference. Always substitute the current quarter’s actual ASP figure.

J2353 vs. J2354: key differences

J2353 and J2354 both describe octreotide injections, but they are not interchangeable. Using the wrong code results in a denial. The core distinction is formulation: J2353 is the depot (long-acting release) form; J2354 covers non-depot (immediate-release) octreotide.

A similar formulation-based split shows up elsewhere in the HCPCS set: J3370 was deleted and replaced once CMS separated out a related dosing form, a reminder that checking whether a code is still active matters as much as picking the right one.

A common transition scenario: a patient starts on J2354 for initial dose titration, then transitions to J2353 once a therapeutic dose is established. Billing J2353 during the titration period (when the immediate-release form is actually being used) results in a claim error. Always confirm the formulation dispensed before selecting the code.

Common billing errors with J2353 and how to avoid them

J2353 denials cluster around a predictable set of errors. Most are preventable with a pre-submission checklist. Similar denial patterns show up with other injectable and device codes, like J7298, whenever the wrong formulation or unit count is billed.

• Incorrect unit count: Billing 1 unit for a 20 mg injection instead of 20 units is the most frequent J2353 unit error. Always calculate units as total milligrams administered.
• Missing or invalid ICD-10 code: Submitting J2353 without a covered diagnosis code (E22.0, E34.00, etc.) triggers an automatic denial. The ICD-10 code must be active, valid for the date of service, and match a covered indication under your MAC’s LCD.
• Missing prior authorization: When your MAC or commercial payer requires PA, submitting without the authorization number results in immediate denial. No PA = no payment, regardless of clinical appropriateness.
• Wrong code (J2353 vs. J2354): Using the depot code when the immediate-release formulation was administered, or vice versa, is a code accuracy error that may also trigger a fraud and abuse flag on audit.
• Incorrect place of service: Billing office (11) when the injection was given in a hospital outpatient setting (22) results in a payment mismatch. The place of service code must reflect where the drug was actually administered.
• Stale ASP rate: Charging based on a prior quarter’s ASP rather than the current quarter’s rate creates a billing discrepancy. Update your charge master at the start of each new quarter.

How practice management software simplifies J2353 billing

Most J2353 billing errors are not clinical mistakes. They are workflow failures: the wrong unit count because the billing team worked from a standing order rather than the actual administered dose; a missing PA because the system had no mechanism to flag it; a stale ICD-10 code because no one updated the superbill after an LCD revision.

Integrated claims management software addresses these workflow failures directly. By linking the clinical administration record to the billing claim, unit counts derive from what was actually documented as administered, not from a template.

PA tracking within the patient record means the billing team sees authorization status before the claim is generated. And when the clinical record is complete, the practice management platform can automatically populate required claim fields from the documentation, reducing manual re-entry errors.

For practices running buy-and-bill workflows on high-cost injectables like Sandostatin LAR Depot, that documentation-to-claim linkage also supports audit readiness. When a MAC requests records to support a J2353 claim, having the administration record, PA approval, and diagnosis documentation all in one place shortens the response timeline substantially.

Digital intake forms that feed directly into the patient record remove the transcription step entirely.

Conclusion

HCPCS Code J2353 is straightforward in concept but demanding in execution. Getting the unit count right, pairing the correct ICD-10 diagnosis, securing prior authorization before the injection date, and keeping documentation audit-ready are each their own workflow requirement. Practices that handle these steps manually accumulate denials; those with integrated billing workflows catch errors before they reach the payer.

Pabau’s claims management software links clinical documentation to J-code billing workflows, helping endocrinology, oncology, and neuroendocrine tumor programs bill J2353 accurately from the first claim. To see how it works in a live environment, book a demo.

Continue your research

Need a claims workflow that keeps up with quarterly ASP changes? Claims management software from Pabau connects clinical documentation to billing submissions for injectable drug codes.

Managing high-cost injectable billing across multiple providers? Practice management software features outlines how integrated platforms reduce manual errors across complex billing workflows.

Need to confirm whether a related J-code is still active? Our guide to J1040 covers a recently deleted methylprednisolone acetate code and its replacement.

Frequently asked questions